Catalyst Pharmaceuticals (CPRX)
(Delayed Data from NSDQ)
$20.38 USD
-0.09 (-0.44%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $20.38 0.00 (0.00%) 7:32 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Brokerage Reports
0 items in cart
Catalyst Pharmaceuticals, Inc. [CPRX]
Reports for Purchase
Showing records 181 - 200 ( 427 total )
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Believe Jacobus is Nothing More Than a Brutum Fulmen; Reit Buy and $9 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Updated Model - Early Firdapse Launch Encouraging
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Catalyst Pharmaceuticals, Inc.
Industry: Medical - Drugs
Initial Data Points From Firdapse Commercial Launch Suggest Strong Momentum, We Believe; Reit Buy and $9 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A